Baxter International

Baxter acquires Gambro

Monday, September 9, 2013 03:49 PM

Baxter International has acquired Sweden-based Gambro, a privately-held global medical technology company and producer of dialysis products.

More... »

Baxter, Coherus Biosciences collaborate

Wednesday, September 4, 2013 12:09 PM

Baxter International and Coherus Biosciences, a San Francisco Bay area-based clinical stage, pure-play biosimilar company, have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada and Brazil. Biosimilars are intended to be used in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases and have the potential to reduce costs and expand patient access.

More... »

Ipsen, Inspiration enter into asset purchase agreement with Baxter on OBI-1

Friday, January 25, 2013 10:32 AM

Ipsen, a global specialty-driven pharmaceutical company, and Inspiration Biopharmaceuticals, a biopharmaceutical company focused on hemophilia, have entered into an Asset Purchase Agreement (APA) whereby healthcare company Baxter International will acquire worldwide rights to OBI-1, a recombinant porcine factor VIII (rpFVIII) in development for congenital hemophilia A with inhibitors and acquired hemophilia A, and Ipsen's industrial facility in Milford, Mass.

More... »

Baxter to acquire Gambro, enhance renal therapies portfolio

Wednesday, December 5, 2012 10:40 AM

Baxter International, a global healthcare company, has entered into a definitive agreement to acquire Gambro, a privately held dialysis product company based in Lund, Sweden, for total consideration of approximately $4 billion.

More... »

Baxter, Onconova form European licensing agreement for anti-cancer compound rigosertib

Wednesday, September 19, 2012 03:11 PM

Baxter International, a developer, manufacturer and marketer of medical products, and Onconova Therapeutics, a discoverer and developer of novel small molecule therapeutics, have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound currently in a phase III study for the treatment of a group of rare hematologic malignancies called myelodysplastic syndromes (MDS) and in a phase II/III study for pancreatic cancer.

More... »

Baxter collaborates with Chatham on Hemophilia B gene therapy

Wednesday, June 6, 2012 01:31 PM

Baxter International, a global, diversified healthcare company, has entered into an exclusive global agreement with Chatham Therapeutics, a private clinical development-stage biotech, for the development and commercialization of  potential treatments for hemophilia B utilizing Chatham's gene therapy technology. 

More... »

Baxter reports positive phase III results for Gammagard Liquid

Monday, April 30, 2012 04:02 PM

Baxter International, a healthcare company based in Deerfield, Ill., has released results from its phase III clinical trial evaluating Gammagard Liquid 10% (Immune Globulin Infusion (Human)) for the treatment of multifocal motor neuropathy (MMN).

More... »

Baxter, Momenta enter $33 million biosimilar development agreement

Friday, December 23, 2011 12:29 PM

Baxter International and Momenta Pharmaceuticals have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars. Biosimilars replicate existing, branded biologics used in the treatment of a variety of diseases including cancer, autoimmune disorders and other chronic conditions. With this collaboration, Baxter will leverage its leading clinical development and biologic manufacturing expertise, global leadership in sterile injectables and global commercial capabilities, while Momenta will provide its expertise in high-resolution analytics, characterization, and product and process development.

More... »

Baxter to acquire Synovis for $260 million

Tuesday, December 13, 2011 11:30 AM

Baxter International and Synovis Life Technologies have reported a definitive agreement for Baxter to acquire Synovis, a provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures. The acquisition complements and will expand the portfolio of Baxter's regenerative medicine and biosurgery franchise, which includes a number of devices and biological products for hemostasis, tissue sealing and adherence.

More... »

Baxter Ventures to invest $200 million in early-stage companies

Friday, July 29, 2011 10:02 AM

Baxter International has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.

More... »